A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in reccurrent squamous cell carcinoma of the head and neck (The Baylor experience)

Annals of Surgical Oncology

Volumn 7, Issue 8, 2000, Pages 588-592

  Lamont, Jeffery P ^a   Nemunaitis, John ^a   Kuhn, Joseph A ^a   Landers, Steven A ^a   McCarty, Todd M ^a,b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b Sammons Tower ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; ONYX 015; UNCLASSIFIED DRUG;

ADENOVIRUS; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; FATIGUE; FEMALE; GENE THERAPY; HEAD CANCER; HUMAN; HUMAN TISSUE; INJECTION PAIN; MALE; MUCOSA INFLAMMATION; NAUSEA; NECK CANCER; PHASE 2 CLINICAL TRIAL; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; UNITED STATES; VOMITING;

EID: 0033835016     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02725338     Document Type: Article

References (21)

1. Salvage treatment for recurrent squamous cell carcinoma of the oral cavity
2. Treatment outcome in recurrent head and neck cancer
3. Prognostic factors in the recurrence of stage I and II squamous cell cancer of the oral cavity
4. Carcinoma of the floor of the mouth: An analysis of treatment results and the sites and causes Of failures
5. Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without so-dium diethyldithiocaramate in recurrent and/or metastatic squamous cell cancer of the head and neck
6. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck
7. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: A southwest oncology group study
8. Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer
9. A phase III randomized trial of cisplatin, methotrexate, cisplatin + methotrexate, and cisplatin + 5-FU in end stage squamous carcinoma of the head and neck
10. Randomized comparison of cisplatin, methotrexate, bleomycin, and vincristine (CABO) versus cisplatin and 5-fluorouracil versus cisplatin, in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC head and neck cancer cooperative group
11. The incidence of p53 mutations increases with progression of head and neck cancer
12. P53 alterations in human squamous cell carcinomas and carcinoma cell lines
13. p53 expression: Predicting recurrence and second primary tumors in head and neck squamous cell carcinoma
14. Pretreatment p53 protein expression correlates with decreased survival in patients with end-stage head and neck cancer
15. Wild type p53 mediates apoptosis by E1A, which is inhibited by E1B
16. Enhanced expression of p53 in human cells infected with metastatic adenoviruses
17. Stabilization of the p53 tumor suppression is induced by adenovirus 5E1A and accompanies apoptosis
18. Efficacy of a replication competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distant effects
19. ONYX-015, and E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
20. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
21. A controlled trial of intra-tumoral ONYX-015, a selectively-replicating adenovirus, in combina-tion with cisplatin and 5-FU in patients with recurrent head and neck cancer